Over 1750 Total Lots Up For Auction at Five Locations - MA 04/30, NJ Cleansweep 05/02, TX 05/03, TX 05/06, NJ 05/08

Chartwise Medical Systems scores Best in KLAS in CDI Software category

Press releases may be edited for formatting or style | February 17, 2016

KLAS independently monitors vendor performance through the active participation of thousands of healthcare organizations. KLAS uses a stringent methodology to ensure all data and ratings are accurate, honest and impartial. For a full list of Best in KLAS winners, visit http://www.klasresearch.com/.

For additional information about the ChartWise 2.0 product, please visit http://www.chartwisemed.com/products.


About ChartWise
ChartWise Medical Systems, Inc., based in Wakefield, RI, is a medical software firm and the developer of ChartWise 2.0, a web-based solution for Computer-Assisted Clinical Documentation Improvement. ChartWise 2.0's clinical intelligence expertise assists physicians and clinical documentation specialists with increased efficiencies and completeness of documentation, queries and workflow. Developed by renowned physician Jon Elion, M.D., ChartWise 2.0 is the only documentation software that translates clinical language used by physicians into accurate diagnostic language required for documentation and reimbursement. ChartWise was selected as a 2015 Red Herring Top 100 North America and Global 100 Winner. ChartWise was also selected as the 2015/2016 KLAS Award Winner for the CDI Software category. For more information, visit www.chartwisemed.com.

About KLAS
KLAS is a research and insights firm on a global mission to improve healthcare delivery by amplifying the provider's voice. Working with thousands of healthcare professionals and clinicians, KLAS gathers data and insights on software, services, and medical equipment to deliver timely reports, trends and statistical overviews. The research directly represents the provider voice and acts as a catalyst for improving vendor performance. Follow KLAS on Twitter at http://www.twitter.com/KLASresearch.

Back to HCB News

You Must Be Logged In To Post A Comment